Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Orphan Drugs

• Publication date

  2013-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/21678707.2013.769875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms

  2013cited by this paper
• Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.

  2012cited by this paper
• F-50 Increased urinary level of neutrophil gelatinase–associated lipocalin (NGAL) in patients with cirrhosis and type 1 HRS

  2012cited by this paper
• Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression.

  2012cited by this paper
• Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome

  2012cited by this paper
• Acute kidney injury and residual renal function

  2012cited by this paper
• Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.

  2012cited by this paper
• Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.

  2012cited by this paper
• Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.

  2011cited by this paper
• Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?

  2011cited by this paper
• Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

  2011cited by this paper
• 592 POSITIVE CARDIAC INOTROPIC EFFECT OF ALBUMIN INFUSION IN RATS WITH CIRRHOSIS AND ASCITES: MOLECULAR MECHANISMS

  2011cited by this paper
• T-32 Positive cardiac inotropic effect of albumin infusion in rats with cirrhosis and ascites: Molecular mechanisms

  2011cited by this paper
• Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.

  2011cited by this paper
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

  2010influential reference
• Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome

  2010cited by this paper
• Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis

  2010cited by this paper
• The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study

  2010cited by this paper
• Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome

  2010cited by this paper
• Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites

  2009cited by this paper
• Renal failure in cirrhosis.

  2009cited by this paper
• Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.

  2009cited by this paper
• Combination Treatment With Octreotide, Midodrine, and Albumin Improves Survival in Patients With Type 1 and Type 2 Hepatorenal Syndrome

  2009cited by this paper
• Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis

  2009cited by this paper
• An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response

  2008cited by this paper
• Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome

  2008cited by this paper
• A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

  2008cited by this paper
• Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK)

  2008cited by this paper
• Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

  2008cited by this paper
• Terlipressin given as i.v. boluses vs terlipressin given as continuous intravenous infusion in patients with cirrhosis and type 1 hepatorenal sindrome(HRS): prelimnary results of a randomized controlled clinical study.

  2008cited by this paper
• Role of NF- (cid:1) B and PI 3-kinase/Akt in TNF- (cid:2) -induced cytotoxicity in microvascular endothelial cells

  2008cited by this paper
• Cirrhotic cardiomyopathy

  2007cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007cited by this paper
• Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome

  2007cited by this paper
• Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost

  2006cited by this paper
• Hepatorenal syndrome

  2005cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cited by this paper
• Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

  2004cited by this paper
• Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

  2004cited by this paper
• New pathophysiological mechanisms in irritable bowel syndrome

  2004cited by this paper
• Effect of terlipressin on blood volume distribution in patients with cirrhosis

  2004cited by this paper
• Prognosis of hepatorenal syndrome – has it changed with current practice?

  2004cited by this paper
• Endothelial nitric oxide synthase-deficient mice exhibit increased susceptibility to endotoxin-induced acute renal failure.

  2004cited by this paper
• Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.

  2003cited by this paper
• Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis

  2003cited by this paper
• Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial

  2003cited by this paper
• Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*

  2002cited by this paper
• Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study

  2002cited by this paper
• Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2

  2002cited by this paper
• Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis

  2002cited by this paper
• Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

  2002cited by this paper
• Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study

  2002cited by this paper
• Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.

  2001cited by this paper
• Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.

  2000cited by this paper
• Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?

  2000cited by this paper
• Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

  1999cited by this paper
• Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

  1999cited by this paper
• Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

  1999cited by this paper
• Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

  1998cited by this paper
• Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome.

  1998cited by this paper
• Time profile of the haemodynamic effects of terlipressin in portal hypertension.

  1997cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis

  1996cited by this paper
• Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis

  1988cited by this paper

• Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

  2016cites this paper